Ramiscal JAB, Stern SI, Wilson AK, et al. Does Residual Invasive Disease in Wide Local Excision after Diagnosis with Partial Biopsy Technique Influence Survival in Melanoma Matched Pair Analysis of Multicenter Selective Lymphadenectomy Trial I and II. J Am Coll Surg. 2022, in press.
Publications
Pembrolizumab Moves Toward EU Approval for Resected Stage IIB/IIC Melanoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pembrolizumab (Keytruda) for use as adjuvant therapy in adult and adolescent patients aged 12 years and older with stage IIB or IIC melanoma following complete resection. Additionally, CHMP recommended expanding the indication for pembrolizumab in advanced unresectable or metastatic and stage III melanoma as adjuvant therapy following complete resection for adolescent patients aged 12 years and older.
EMA adopts positive opinion for Keytruda in melanoma following complete resection
A committee of the European Medicines Agency recommended the approval for expanded use of Keytruda (pembrolizumab) as a standalone therapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma who have undergone complete resection.
Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells
Accumulation of senescent cells in various tissues has been reported to have a pathological role in age-associated diseases.